LIBTAYO® (cemiplimab-rwlc) Injection 350 mg

LIBTAYO dosing

The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks. Treatment should be continued until1:

  • aNSCLC: Disease progression or unacceptable toxicity
  • aCSCC and aBCC: Disease progression, unacceptable toxicity, or up to 24 months
Learn more about LIBTAYO Dosing
  • ALK=anaplastic lymphoma kinase; aNSCLC=advanced non–small cell lung cancer; EGFR=epidermal growth factor receptor; FDA=Food and Drug Administration; HHI=hedgehog pathway inhibitor; laBCC=locally advanced basal cell carcinoma; laCSCC=locally advanced cutaneous squamous cell carcinoma; mCSCC=metastatic cutaneous squamous cell carcinoma; NSCLC=non–small cell lung cancer; PD-L1=programmed death receptor-1; ROS1=ROS proto-oncogene 1, receptor tyrosine kinase.

Help eligible patients access LIBTAYO and navigate the health
insurance process.